Pathophysiological and Prognostic Importance of an ExtraCardiac Comorbidity Burden in Patients with Heart Failure with Preserved Ejection Fraction
An extracardiac comorbidity burden in patients with HFpEF is associated with relevant pathophysiological features characterized by impaired exercise capacity, worse ventilatory efficiency, impaired O<sub>2</sub> extraction and utilization in the periphery, and poor clinical outcomes.
Authors
- Masaru Obokata (ORCID: https://orcid.org/0000-0002-5473-0688)
- Toshimitsu Kato (ORCID: https://orcid.org/0000-0002-0011-7589)
- Naoki Yuasa (ORCID: https://orcid.org/0000-0002-2090-1530)
- Hideki Ishii (ORCID: https://orcid.org/0000-0003-4348-0123)
- Yuta Tani (ORCID: https://orcid.org/0009-0002-8942-6448)
- Kazuki Kagami (ORCID: https://orcid.org/0000-0002-1743-4409)
- Tomonari Harada (ORCID: https://orcid.org/0000-0003-4662-2991)
- Ayami Naito (ORCID: https://orcid.org/0009-0009-8304-8651)
- Yuki Saito (ORCID: https://orcid.org/0000-0001-6432-6403)
- Yasuo Okumura (ORCID: https://orcid.org/0000-0002-5734-4811)
- Naoki Wada (ORCID: https://orcid.org/0000-0002-3816-6247)
- Tomoaki Ishii
- Fumitaka Murakami
Institutions
- Nihon University (JP)
- Gunma University (JP)
- Numazu City Hospital (JP)
- National Defense Medical College (JP)
Publication Details
- Journal
- CJC Open
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1016/j.cjco.2025.01.004
- Citations
- 1
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Japan Agency for Medical Research and Development
- Boehringer Ingelheim Japan
- Nippon Shinyaku
- Daiichi-Sankyo
- Fukuda Foundation for Medical Technology
- Japanese Circulation Society
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Otsuka Pharmaceutical
- Teijin Pharma
- Mitsubishi Tanabe Pharma Corporation
- Pfizer Japan
- Japan Society for the Promotion of Science